Considering its multiple metabolic benefits, a large number of clinical trials have been registered to evaluate the therapeutic efficacy of several human FGF21 analogues for the treatments of type 2 diabetes (T2DM), dyslipidaemia and non‐alcoholic fatty liver disease (NAFLD).11 Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.